secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001193125-25-082809
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Pharmaceuticals amends bylaws, tightens stockholder nomination and meeting rules
--------------------------------------------------------------------------------

- Quorum threshold changed from majority of outstanding shares to majority of voting power.
- Stockholder nominees limited to number of directors to be elected; substitute nominees prohibited.
- Advance notice window widened: alternative window applies if annual meeting delayed >70 days (was 30).
- Mandatory indemnification and expense advancement for directors/officers expanded to maximum extent allowed.
- Exclusive forum provisions clarified, including U.S. federal district courts for Securities Act claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312525082809/0001193125-25-082809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312525082809/d905282d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-082809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer